Fast-dissolving tablets (FDTs), also known as orally disintegrating tablets, have emerged as an advanced oral drug delivery system designed to improve patient convenience, compliance, and therapeutic effectiveness. These tablets rapidly disintegrate in the oral cavity without the need for water, making them especially beneficial for pediatric, geriatric, dysphagic, and bedridden patients. The rapid disintegration of FDTs is primarily driven by formulation factors such as superdisintegrants, porous tablet structures, and hydrophilic excipients that enhance saliva penetration and tablet breakup. Recent developments in excipient technology and manufacturing techniques have significantly improved the performance of FDTs. Methods such as direct compression, freeze-drying, spray drying, sublimation, and moulding are widely employed to produce tablets with optimal porosity and mechanical strength. Advanced patented technologies further enhance taste masking, stability, and rapid drug release. In addition to improving patient acceptability, FDTs may contribute to a faster onset of action and, in some cases, improved bioavailability through pre-gastric absorption. FDTs are now used across multiple therapeutic areas, including analgesics, antiemetics, antihistamines, cardiovascular agents, and central nervous system drugs. Ongoing research is exploring natural polymers, novel superdisintegrants, and nanotechnology-based approaches to further optimize tablet performance. Overall, fast-dissolving tablets represent a significant innovation in oral drug delivery, combining patient-centred design with pharmaceutical advancements to address modern therapeutic needs.